Paper Details

  1. Home
  2. Paper Details

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

Author: , BrownNathaniel A, CondreayLynn D, CrowtherLynn M, DienstagJules L, GoodmanZachary, GrimmIan S, HusaPetr, KarayalcinSelim, McPhillipsPenny J, PerrilloRobert P, SchiffEugene R, WoessnerMary A, de ManR A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

The study assesses the effectiveness of lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had failed interferon therapy previously.
Paper Details　
Original Abstract of the Article :
Lamivudine is effective in treatment-naive patients with chronic hepatitis B, but its role in interferon nonresponders has not been described. We assessed lamivudine treatment, with or without added interferon, in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B who had faile...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0168-8278(03)00076-x

データ提供：米国国立医学図書館（NLM）

Lamivudine: A New Oasis in the Desert of Hepatitis B

Hepatitis B, a viral infection that affects the liver, can lead to serious complications, including cirrhosis and liver cancer. This study examined the effectiveness of lamivudine, an antiviral medication, in treating hepatitis B in patients who had not responded to interferon therapy. The researchers investigated the use of lamivudine alone or in combination with interferon in patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg). Their findings showed that lamivudine, even in interferon nonresponders, could effectively manage chronic hepatitis B, offering a new avenue for treatment.

Exploring New Paths in Hepatitis B Treatment

This research expands our understanding of hepatitis B treatment, offering a valuable alternative for patients who haven't responded to interferon therapy. It's like finding a new route through a vast desert, offering hope and possibilities for those struggling with this chronic condition. This study emphasizes the importance of individualized treatment approaches, considering patient characteristics and treatment history to maximize therapeutic outcomes.

Navigating the Desert of Hepatitis B

This study provides valuable insights into the evolving landscape of hepatitis B treatment, highlighting the importance of exploring new therapeutic options. It's like discovering a hidden oasis in a desert of uncertainty, offering a glimmer of hope for patients with this challenging condition. The findings underscore the need for continued research to develop even more effective treatments for hepatitis B, improving the lives of individuals affected by this global health concern.

Dr. Camel's Conclusion

This research sheds light on the importance of finding innovative solutions for treating hepatitis B. It's like searching for a hidden oasis in a vast and unforgiving desert, where each new discovery offers a glimmer of hope. This study demonstrates the value of lamivudine as a viable treatment option, offering hope and possibilities to patients facing the challenges of hepatitis B.
Date :
  1. Date Completed 2004-01-22
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

12763376

DOI: Digital Object Identifier

10.1016/s0168-8278(03)00076-x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.